Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Disease system analysis: basic disease progression models in degenerative disease.

Teun M Post1, Jan I Freijer, Joost DeJongh

  • 1Leiden Experts on Advanced Pharmacokinetics and Pharmacodynamics, Leiden, The Netherlands.

Pharmaceutical Research
|July 20, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Simulation Framework to Investigate Efficacy and Ocular Safety of Belantamab Mafodotin Combinations in Relapsed/Refractory Multiple Myeloma.

CPT: pharmacometrics & systems pharmacology·2026
Same author

Model-Informed Drug Development for Daprodustat Supports the Design of Individualized Dosing Regimens in Chronic Kidney Disease Patients With Anemia.

Clinical pharmacology and therapeutics·2025
Same author

Tutorial on Conditional Simulations With a Tumor Size-Overall Survival Model to Support Oncology Drug Development.

CPT: pharmacometrics & systems pharmacology·2025
Same author

Development of a Joint Tumor Size-Overall Survival Modeling and Simulation Framework Supporting Oncology Development Decision-Making.

CPT: pharmacometrics & systems pharmacology·2025
Same author

Defining preclinical efficacy with the DNAPK inhibitor AZD7648 in combination with olaparib: a minimal systems pharmacokinetic-pharmacodynamic model.

Journal of pharmacokinetics and pharmacodynamics·2025
Same author

Integrated Longitudinal Population Dose-Hemoglobin Response of Daprodustat Following Dose Titration in Patients With Anemia in Chronic Kidney Disease.

Clinical pharmacology and therapeutics·2025

A new disease progression model distinguishes between symptomatic and protective drug effects for conditions like type 2 diabetes and Parkinson's disease. This model helps understand treatment impacts and disease trajectories over time.

Area of Science:

  • Pharmacometrics
  • Systems Pharmacology
  • Disease Modeling

Background:

  • Degenerative diseases like type 2 diabetes mellitus and Parkinson's disease pose significant health challenges.
  • Understanding disease progression and treatment effects is crucial for effective management.

Purpose of the Study:

  • Introduce a family of disease progression models to describe disease status.
  • Differentiate between symptomatic and protective drug effects in degenerative diseases.

Main Methods:

  • Utilize a progression rate (Rdp) impacting synthesis/elimination parameters in an indirect response model.
  • Model symptomatic effects as disease-dependent/independent influences on parameters.
  • Incorporate protective drug effects as disease-dependent/independent influences on Rdp.

Related Experiment Videos

Main Results:

  • Simulations reveal distinct profiles for symptomatic and protective treatment effects.
  • Symptomatic treatments show temporary improvement followed by deterioration.
  • Protective treatments demonstrate lasting reduction or reversal of disease progression during therapy.

Conclusions:

  • Disease system analysis provides a basis for distinguishing symptomatic vs. protective drug effects.
  • Enables identification of exposure-response relationships over the disease course.